Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Inclusion Criteria: * Patients 18 years or older with at least one of each component cardiovascular diagnosis testing (ECG and Echo) in the YNHHS. * Patients with a diagnosis of HFpEF or HFmrEF * Participant from Phase I TRACE-AI Study with AI-ECG and AI-Echo screen in the preceding 36 months Exclusion Criteria: * Patients who have opted out of research studies * Patients with cardiac amyloid diagnostic test in the past 36 months * Patients with hypertrophic cardiomyopathy or end-stage renal disease * Pregnant women * Patients unable or unwilling to provide informed consent * Non-English speakers and cognitively impaired individuals who are unable to comprehend the consent and the on-screen instructions on the application, which are in English.